Biogen takes Creative Biolabs to court over antibody
19-03-2020
Biogen blocking bid rejected; signs $2.4bn deal
28-02-2020
Biogen to pay $1.25bn to Forward Pharma in licensing deal
19-01-2017
PictureDesignSwiss / Shutterstock.com
US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biogen, Mylan, Tecfidera, dimethyl fumarate, patent challenge, Patent Trial and Appeal Board, PTAB, obviousness, disease modifying drug, multiple sclerosis
